TechCrunch Startup News
Orakl Oncology combines data and biology to bring new drugs to cancer patients
Dec 4, 2024
The podcast dives into the alarming rise of cancer among younger adults and the staggering failure rates of new drug compounds in clinical trials. Fanny Jaulin discusses the need for innovative trial designs to improve outcomes. It highlights how a startup is leveraging AI to revolutionize drug discovery by tailoring treatments to individual patient profiles, particularly for colorectal and pancreatic cancers. Their recent funding successes signal a promising advance in the realm of precision medicine.
03:38
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Fanny Jolin emphasizes that redesigning clinical trials is crucial for improving drug development success rates amidst rising cancer cases.
- Oracle Oncology leverages artificial intelligence to innovate drug discovery by integrating biological insights and data with advanced organoid testing methods.
Deep dives
Challenges in Cancer Drug Development
Cancer incidence is rising, particularly among younger adults, and most new drug compounds fail to advance through clinical trials. French entrepreneur Fanny Jolin highlights that the underlying problem often lies in the design of these clinical trials. She emphasizes that a drug's failure in trials does not necessarily indicate its ineffectiveness, pointing to the need for smarter trial methodologies. This situation underlines the importance of innovating within the clinical trial process to improve outcomes for cancer treatments.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
